Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

BACKGROUND: Antiangiogenic agents have improved the prognosis of non-squamous non-small–cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor’s characteristics or comorbidities. Much less information is available a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Vergnenègre, Alain, Basse, Victor, Le Garff, Gwenaelle, Bylicki, Olivier, Dubos-Arvis, Catherine, Comet, Bénédicte, Marcq, Marie, Le Treut, Jacques, Auliac, Jean-Bernard, Madroszyk, Anne, Fraboulet, Gislaine, Crequit, Jacky, Thomas, Pascal, Paleiron, Nicolas, Monnet, Isabelle
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938186/
https://ncbi.nlm.nih.gov/pubmed/31920391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S219984
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados